Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-716-3 | CAS number: 109-89-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Dec 2009 - Feb 2010
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 010
- Report date:
- 2010
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Version / remarks:
- July 2016
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Quality Assurance statement, 4 May 2010
- Type of assay:
- mammalian cell gene mutation assay
Test material
- Reference substance name:
- Diethylamine
- EC Number:
- 203-716-3
- EC Name:
- Diethylamine
- Cas Number:
- 109-89-7
- Molecular formula:
- C4H11N
- IUPAC Name:
- diethylamine
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Lot/batch No.: DEJ30990H0SOURCE OF TEST MATERIAL
- Analytical purity: >= 99.9 %
- Expiration date of the lot/batch: 30 Oct. 2011
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: 15 to 25°C
- Solubility and stability of the test substance in the solvent/vehicle: preliminary solubility tests revealed limit concentration of 906.8 µg/mL in culture medium, solubility in DMSO of at least 90.68 mg/mL
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: solution preperation under subdued lighting by formulating the test article in DMSOn(vortex mixing if required); The solutions were protected from light and used within 2 hours
Method
- Target gene:
- hypoxanthine-guanine phosphoribosyl transferase (HPRT)
Species / strain
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Details on mammalian cell type (if applicable):
- - Properly maintained: yes
- Periodically checked for Mycoplasma contamination: yes
- Periodically "cleansed" against high spontaneous background: yes
- Metabolic activation:
- with and without
- Metabolic activation system:
- Type and composition of metabolic activation system:
- source of S9 : Molecular Toxicology Incorporated, USA; Sprague Dawley rats induced with Aroclor 1254
- method of preparation of S9 mix : G6P (180 mg/mL), NADP (25 mg/mL), KCl (150mM) and S9 were mixed in ratio 1:1:1:2
- concentration or volume of S9 mix and S9 in the final culture medium: 1 mL of S9-mix to each cell culture (19 mL)
- quality controls of S9 (e.g., enzymatic activity, sterility, metabolic capability): Sterility test, protein content analysis, test for presence of adventitious agents, promutagen activation - Test concentrations with justification for top dose:
- Range finder: 22.86; 45.71; 91.43; 182.9; 365.7; 731.4 µg/mL (with and without S-9 mix)
Experiment 1: 100, 200, 300, 350, 400, 450, 500, 550, 650, 731.4 (without S-9 mix)
100, 200, 300, 400, 500, 550, 600, 650, 700, 731.4 (with S-9 mix)
Experiment 2: 50, 100, 200, 300, 350, 400, 450, 500, 600, 731.4 (without S-9 mix)
100, 200, 300, 400, 450, 500, 550, 600, 650, 731.4 (with S-9 mix)
- Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
Controls
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Positive controls:
- yes
- Positive control substance:
- 4-nitroquinoline-N-oxide
- benzo(a)pyrene
- Remarks:
- 4-nitroquinoline 1-oxide: 0.10/0.15 µg/ml (without S-9 mix); Benzo[a]pyrene: 2.00/3.00 µg/ml (with S-9 mix)
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Exposure duration: 3 hours
- Expression time (cells in growth medium): 7 days
SELECTION AGENT (mutation assays): 6GT, 15 µg/ml
NUMBER OF REPLICATIONS: 2 (single cultures used for the positive control treatments) - Evaluation criteria:
- For valid data, the test article was considered to induce forward mutation at the hprt locus in mouse lymphoma L5178Y cells if:
The mutant frequency at one or more concentrations was significantly greater than that of the negative control (p≤0.05)
There was a significant concentration relationship as indicated by the linear trend analysis (p≤0.05)
The effects described above were reproducible.
Results that only partially satisfy the assessment criteria described above are considered on a case-by-case basis. - Statistics:
- Statistical significance of mutant frequencies was carried out according to the UKEMS guidelines. Thus the control log mutant frequency (LMF) was compared with the LMF from each treatment concentration, and secondly the data were checked for a linear trend in mutant frequency with test article treatment. These tests require the calculation of the heterogeneity factor to obtain a modified estimate of variance.
Results and discussion
Test results
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Accordingly, for Experiment 1 ten concentrations, ranging from 100 to 731.4 µg/mL, were tested in the absence and presence of S 9. Following the treatment incubation period, the highest two concentrations in the absence of S-9 and the highest three concentrations in the presence of S-9 (650 to 731.4 µg/mL in each case) were not plated for survival due to excessive toxicity. Seven days after treatment, the highest two remaining concentrations in the absence of S-9 (500 and 550 µg/mL) and the highest remaining concentration in the presence of S 9 (600 µg/mL) were considered too toxic for selection to determine viability and 6TG resistance. All other concentrations in the absence and presence of S-9 were selected. The highest concentrations selected were 450 µg/mL in the absence of S 9 and 550 µg/mL in the presence of S 9, which gave 10% and 7% RS, respectively. In the presence of S-9, no concentration gave 10 20% RS. Cultures treated at 500 and 550 µg/mL gave 21% and 7% RS, respectively, therefore both concentrations were analysed.
In Experiment 2, ten concentrations, ranging from 50 to 731.4 µg/mL in the absence of S-9 and from 100 to 731.4 µg/mL in the presence of S 9, were tested. Following the treatment incubation period, the highest two concentrations in the absence of S-9 (600 and 731.4 µg/mL) were not plated for survival due to excessive toxicity. Seven days after treatment, the highest remaining concentration in the absence of S 9 (500 µg/mL) and the highest four concentrations in the presence of S 9 (550 to 731.4 µg/mL) were considered too toxic for selection to determine viability and 6TG resistance. All other concentrations in the absence and presence of S-9 were selected. However, the concentration of 300 µg/mL in the presence of S-9 was later rejected from analysis due to extreme heterogeneity for viability. Marked heterogeneity (also for viability) was observed at concentrations of 50 µg/mL in the absence of S-9 and 450 µg/mL in the presence of S-9, but these were included for comparative purposes. The highest concentrations analysed were 450 µg/mL in the absence of S 9 and 500 µg/mL in the presence of S 9, which gave 10% and 13% RS, respectively.
Any other information on results incl. tables
Tab. 1 Summary of mutation data experiment 1
Experiment 1 (3 hours treatment in the absence and presence of S-9 mix)
Treatment (µg/mL) |
-S-9 |
Treatment (µg/mL) |
+S-9 |
||||||||
|
% RS |
MF§ |
|
% RS |
MF§ |
||||||
0 |
|
100 |
4.80 |
|
0 |
|
100 |
3.57 |
|
||
100 |
|
72 |
3.25 |
NS |
100 |
|
96 |
3.14 |
NS |
||
200 |
|
74 |
4.91 |
NS |
200 |
|
69 |
2.75 |
NS |
||
300 |
|
67 |
2.03 |
NS |
300 |
|
62 |
3.91 |
NS |
||
350 |
|
43 |
5.24 |
NS |
400 |
|
62 |
4.65 |
NS |
||
400 |
|
29 |
7.07 |
NS |
500 |
|
21 |
2.87 |
NS |
||
450 |
|
10 |
6.85 |
NS |
550 |
|
7 |
6.33 |
NS |
||
Linear trend |
NS |
Linear trend |
NS |
||||||||
NQO |
|
|
|
|
B[a]P |
|
|
|
|
||
0.1 |
|
44 |
44.33 |
|
2 |
|
52 |
21.21 |
|
||
0.15 |
|
51 |
56.73 |
|
3 |
|
23 |
56.04 |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
§: 6TG resistant mutants/106 viable cells 7 days after treatment
%RS: Percent relative survival adjusted by post treatment cell counts
NS: Not significant
Tab. 2 Summary of mutation data experiment 2
Experiment 2 (3 hours treatment in the absence and presence of S-9 mix)
Treatment (µg/mL) |
-S-9 |
Treatment (µg/mL) |
+S-9 |
||||||||
|
% RS |
MF§ |
|
% RS |
MF§ |
||||||
0 |
|
100 |
2.59 |
|
0 |
|
100 |
2.49 |
|
||
50 |
$$ |
80 |
1.85 |
|
100 |
|
127 |
3.84 |
NS |
||
100 |
|
71 |
2.38 |
NS |
200 |
|
76 |
3.36 |
NS |
||
200 |
|
68 |
3.50 |
NS |
400 |
|
45 |
2.70 |
NS |
||
300 |
|
48 |
2.28 |
NS |
450 |
$$ |
30 |
2.96 |
|
||
350 |
|
27 |
4.48 |
NS |
500 |
|
13 |
5.28 |
NS |
||
400 |
|
18 |
3.32 |
NS |
|
|
|
|
|
||
450 |
|
10 |
10.10 |
* |
|
|
|
|
|
||
Linear trend |
|
* |
Linear trend |
|
NS |
||||||
NQO |
|
|
|
|
B[a]P |
|
|
|
|
||
0.1 |
|
61 |
24.70 |
|
2 |
|
58 |
39.09 |
|
||
0.15 |
|
41 |
21.20 |
|
3 |
|
32 |
69.84 |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
§: 6TG resistant mutants/ 106 viable cells 7 days after treatment
%RS: Percent relative survival adjusted by post treatment cell counts
NS: Not significant
* : Comparison of each treatment with control: Dunnett#s test (one-sided), significant at 5% level
*,**,*** : Test for linear trend: χ2 (one-sided), significant at 5%, 1% and 0.1% level respectively
$$ : Treatment has marked heterogeneity for viability but is included for comparative purposes
Applicant's summary and conclusion
- Conclusions:
- The test substance did not induce mutation at the hprt locus of L5178Y mouse lymphoma cells under the tested conditions.
- Executive summary:
The test substance was investigated for mutation at the hprt locus in mouse lymphoma cells using a fluctuation protocol. The study consisted of a cytotoxicity range-finding experiment followed by two independent experiments (with and without rat S9 metabolic activation). The test article was formulated in DMSO. In the range-finding study concentrations of 22.86 - 731.4 µg/mL were tested. The highest concentration to provide more than 10% survival was 365.7 µg/mL. In experiment 1 ten concentrations (100 - 731.4µg/mL) were tested in the absence and presence of metabolic activation. Seven days after treatment a concentration of 450 µg/mL without S9-mix and 550 µg/mL with S9-mix gave 10% and 7% relative survival, respectively. In experiment 2, concentrations of 50 - 731.4 µg/mL without S9 -mix and 100 - 731.4 µg/mL with S9 mix were tested. Relative survival of 10% and 13% were determined for 450 µg/mL with S9-mix and 500 µg/mL without S9-mix, respectively. Positive and negative control data indicated the study validity. Testing with concentrations up to toxicity (450 µg/mL) in the abscence of S9 in experiment 2 revealed a significant increase in mutant frequency. However, the result was not reproducable with experiment 1and according to the acceptance criteria not of biological relevance. In conclusion, the test substance did not induce mutation at the hprt locus under the test conditions employed in this study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
